Cost-Effectiveness Analysis of Bevacizumab Combined with Lomustine in the Treatment of Progressive Glioblastoma
Key Findings
Compared to Lomustine alone, the combination of Bevacizumab and Lomustine increased the total treatment cost from $2,646.70 to $23,650.98. The health-adjusted life years (QALYs) for the combination therapy increased from 0.26 QALYs to 0.51 QALYs, representing an increment of 0.25 QALYs. The incremental cost-effectiveness ratio (ICER) was $84,071.12.
Conclusion
From the perspective of payers in China, Bevacizumab and Lomustine combination therapy as a first-line treatment for GBM is not a cost-effective option. However, considering the survival advantages this regimen may offer for this rare disease, it may still be one of the clinical treatment options for this patient population.
Practical Solutions and Value
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians.
In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.
By using AI, clinics can enhance their workflows and improve patient outcomes, reducing paper routine. Learn more about how we can help at aidevmd.com.
